Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.68 |
| ▸ | POLB | P06746 | 7/20 | 0.68 |
| ▸ | GAA | P10253 | 5/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13295761 | 0.85 | MAPT (0.71) | MAPTKDM4EALDH1A1POLBGAA | |
| SCHEMBL16335038 | 0.82 | MAPT (0.71) | MAPTKDM4EALDH1A1POLBGAA | |
| SCHEMBL5228867 | 0.78 | MAPT (0.54) | MAPTKDM4EALDH1A1POLBGAA | |
| SCHEMBL5943130 | 0.76 | KMT2A (0.64) | MAPTKDM4EALDH1A1POLBGAA | |
| SCHEMBL844336 | 0.72 | BCL2L1 (0.53) | KDM4EALDH1A1KMT2AMEN1TDP1 | |
| Acridine SCHEMBL29143509 | 0.71 | ALDH1A1 (0.62) | MAPTKDM4EALDH1A1POLBGAA | |
| SCHEMBL29438783 | 0.71 | BCL2L1 (1.00) | RAB9ABCL2L1L3MBTL1 | |
| Acridine SCHEMBL9644821 | 0.71 | ALDH1A1 (0.62) | MAPTKDM4EALDH1A1GAAKMT2A | |
| SCHEMBL93858 | 0.71 | BCL2L1 (1.00) | RAB9ABCL2L1L3MBTL1 | |
| Acridine SCHEMBL8643076 | 0.70 | ALDH1A1 (0.68) | MAPTKDM4EALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014207213-A1 | NOVEL INHIBITORS OF PROTEIN KINASE C EPSILON SIGNALING | MEDIZINISCHE UNIVERSITÄT INNSBRUCK (AT) | 2014-12-31 | — | — | WO | disclosed |
| US-8884017-B2 | 2-heteroarylcarboxylic acid amides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20120202842-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2012-08-09 | — | — | US | disclosed |
| US-8076355-B2 | 2-heteroarylcarboxylic acid amides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER SCHERING PHARMA AG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1461335-B1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | FMR LLC | 2005-06-02 | — | — | US | disclosed |
| EP-1461335-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003055878-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222378-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | MAPT 1209/4885KDM4E 1522/4885ALDH1A1 1358/4885 |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | MAPT 1628/4885KDM4E 1345/4885ALDH1A1 2905/4885 |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | CHRNA2, CHRNA7, CHRNA3 | MAPT 3031/4885KDM4E 1934/4885ALDH1A1 2223/4885 |
| US-20120202842-A1 | 2-HETEROARYLCARBOXYLIC ACID AMIDES | HCAR2, HCAR1, GRIN2A | MAPT 1209/4885KDM4E 1522/4885ALDH1A1 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.